RCM
ESLAW icon

Robinson Capital Management’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Robinson Capital Management’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,805
Closed -$759 – 126
2024
Q3 		$759 Hold
11,805
– – ﹤0.01% 181
2024
Q2 		$815 Hold
11,805
– – ﹤0.01% 175
2024
Q1 		$816 Hold
11,805
– – ﹤0.01% 171
2023
Q4 		$354 Hold
11,805
– – ﹤0.01% 182
2023
Q3 		$1.75K Sell
11,805
-11,805
-50% -$1.95K ﹤0.01% 183
2023
Q2 		$1.68K Buy
23,610
+11,805
+100% +$807 ﹤0.01% 199
2023
Q1 		$1.03K Buy
+11,805
New +$771 ﹤0.01% 243

Other funds holding ESLAW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Robinson Capital Management's ESLAW Position: Q4 2024 in Review

Robinson Capital Management sold out of Estrella Immunopharma Warrant (ESLAW) in Q4 2024, closing a stake of 11,805 shares — an estimated $759 sold.

Robinson Capital Management first reported a position in ESLAW in Q1 2023 and held it in 7 quarters. The position peaked at $1.75K in Q3 2023. 11 funds tracked by Wall St. Rank hold ESLAW as of Q4 2024.

  • Robinson Capital Management reported no remaining Estrella Immunopharma Warrant position as of Q4 2024 after selling out during the quarter.
  • Robinson Capital Management sold 11,805 Estrella Immunopharma Warrant shares in Q4 2024, an estimated $759.
  • Robinson Capital Management first reported a position in Estrella Immunopharma Warrant in Q1 2023 and held it in 7 quarters.
  • Robinson Capital Management's Estrella Immunopharma Warrant position peaked at $1.75K in Q3 2023.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q4 2024.

Based on Robinson Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.